Loading data for ANNX — first visit, this takes a few seconds.
Annexon Inc. (ANNX)
NasdaqGS: ANNX
· Real-Time Price · USD
5.07
-0.11 (-2.12%)
At close: Aug 21, 2026, 8:00 PM
5.13
+1.18%
After-hours: 7:49 PM
The price, the headline numbers and the latest news, in one place.
Annexon Inc. (ANNX) Stock Price, Analysis & Data
-2.12% (1D)
No data available
| Bid | 3.75 |
| Market Cap | 961.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -202.67M |
| 1.22 | |
| -1.13 | |
| n/a | |
| -4.67 | |
| P/B (ttm) | 4.76 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 9, 2026 |
| Ask | 6.48 |
| Volume | 1,362,405 |
| Avg. Volume (20D) | 3,625,903 |
| Open | 5.24 |
| Previous Close | 5.18 |
| Day's Range | 5.02 - 5.28 |
| 52-Week Range | 2.03 - 7.18 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 92
Stock Exchange NasdaqGS
Ticker Symbol ANNX
Website https://www.annexonbio.com
Financial Performance
In 2025, Annexon's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -206.69M, an increase of 49.56%.
Financial StatementsEarnings Surprise
Annexon has released their quarterly earnings on Aug 12, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.28 misses estimates by -0.04, with 17.65% YoY growth.
Annexon Inc. is scheduled to release its earnings on Nov 9, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2